The ELN 2017 system starts to incorporate knowledge about the impact of co-occurring mutations on outcome; specifically, the favorable prognosis of NPM1-mutated AML is noted to be contingent on a low FLT3-ITD mutational burden. The gene discussed is NPM1; the disease is acute myeloid leukemia.